For early-stage HER2+ breast cancer patients with low tumor burden and no lymph node metastasis, consideration may be given to implementing a regimen consisting of dual-targeted therapy alone, without the inclusion of chemotherapeutic agents (22). This evidence concerns the gene ERBB2 and neoplasm.